Lixte Stock Based Compensation from 2010 to 2024

LIXT Stock  USD 1.95  0.11  5.98%   
Lixte Biotechnology Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals
 
Stock Based Compensation  
First Reported
2007-03-31
Previous Quarter
130.7 K
Current Value
-233.6 K
Quarterly Volatility
296.8 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 17 K, Other Operating Expenses of 2.7 M or EBITDA of 3.4 K, as well as many indicators such as Price To Sales Ratio of 9.35, Dividend Yield of 0.0011 or PTB Ratio of 1.18. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Lixte Biotechnology Holdings over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Lixte Biotechnology's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation10 Years Trend
Slightly volatile
   Stock Based Compensation   
       Timeline  

Lixte Stock Based Compensation Regression Statistics

Arithmetic Mean843,170
Geometric Mean599,001
Coefficient Of Variation75.86
Mean Deviation427,492
Median785,612
Standard Deviation639,597
Sample Variance409.1B
Range2.5M
R-Value0.44
Mean Square Error355.8B
R-Squared0.19
Significance0.10
Slope62,720
Total Sum of Squares5.7T

Lixte Stock Based Compensation History

2024858.4 K
2023773.2 K
20221.5 M
20212.6 M
20201.3 M
2019748.7 K
2018785.6 K

Other Fundumenentals of Lixte Biotechnology

Lixte Biotechnology Stock Based Compensation component correlations

0.96-0.97-0.760.241.0-0.30.460.91-0.660.350.580.950.94-0.110.01
0.96-1.0-0.840.210.96-0.40.420.88-0.710.340.640.980.98-0.35-0.27
-0.97-1.00.83-0.22-0.970.38-0.43-0.890.72-0.34-0.63-0.97-0.970.320.23
-0.76-0.840.83-0.45-0.750.38-0.51-0.720.71-0.69-0.41-0.81-0.820.590.43
0.240.21-0.22-0.450.240.130.660.25-0.010.480.040.160.17-0.12-0.06
1.00.96-0.97-0.750.24-0.290.460.91-0.660.340.580.950.94-0.10.01
-0.3-0.40.380.380.13-0.290.16-0.450.18-0.21-0.66-0.45-0.460.510.38
0.460.42-0.43-0.510.660.460.160.29-0.540.29-0.130.410.40.0-0.02
0.910.88-0.89-0.720.250.91-0.450.29-0.530.470.660.90.89-0.18-0.04
-0.66-0.710.720.71-0.01-0.660.18-0.54-0.53-0.3-0.05-0.7-0.70.30.22
0.350.34-0.34-0.690.480.34-0.210.290.47-0.30.060.350.35-0.3-0.09
0.580.64-0.63-0.410.040.58-0.66-0.130.66-0.050.060.660.67-0.38-0.29
0.950.98-0.97-0.810.160.95-0.450.410.9-0.70.350.661.0-0.3-0.22
0.940.98-0.97-0.820.170.94-0.460.40.89-0.70.350.671.0-0.34-0.27
-0.11-0.350.320.59-0.12-0.10.510.0-0.180.3-0.3-0.38-0.3-0.340.89
0.01-0.270.230.43-0.060.010.38-0.02-0.040.22-0.09-0.29-0.22-0.270.89
Click cells to compare fundamentals

About Lixte Biotechnology Financial Statements

Lixte Biotechnology shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Lixte Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Lixte Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lixte Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Stock Based Compensation773.2 K858.4 K
Stock Based Compensation To Revenue 2.47  2.20 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.